Aims Human atherosclerotic plaques express markers of macrophage/dendritic cells as well as high levels of inflammatory proteins such as secreted phospholipase A 2 type IIA (sPLA 2 -IIA). To understand the cellular changes associated with the progress of atherosclerosis, we evaluated the role of sPLA 2 -IIA in mediating monocyte recruitment and differentiation into antigen-presenting cells.
Introduction
Atherosclerosis is a complex process characterized by lipid accumulation in the arterial wall, and it is accompanied by a local inflammatory response in which innate and adaptive immune mechanisms play key roles in plaque formation. [1] [2] [3] The inflammatory response is mediated by functional changes in endothelial cells, T lymphocytes, monocytes/ macrophages, and smooth muscle cells (SMC). 4 Recently, dendritic cells (DCs), derived from monocyte precursors, have also been reported to participate in the atherosclerotic process by activating T cells. 5, 6 Their occurrence in atherosclerotic lesions, as well as in the healthy intima, predisposes them to the development of atherosclerosis, as it has been demonstrated in both human and animal models. [7] [8] [9] In keeping with this, the expression of DC markers, including CD80 or DC-SIGN (dendritic cell-specific ICAM-3 grabbing non-integrin), has been shown in human atherosclerotic plaques. 10 And, since these markers mediate adhesion and endocytosis, a fundamental aspect of DC function, it has been suggested that their expression may potentially have critical functional implications.
In their immature form, DCs are equipped with receptors to become activated when exposed to pathogen-associated molecular patterns. After antigen uptake, DCs migrate and differentiate to phenotypically and functionally mature DCs. These DCs, depending on the maturation state and the local microenvironment, may act to induce immunological tolerance and/or regulation of Tcell-mediated immunity. [11] [12] [13] A multitude of signals, including bacterial components such as LPS, or pro-inflammatory factors such as TNFa or IL-1b, can promote the maturation of DCs inducing a switch from an immature stage to a stage of strong T cellstimulatory capacity.
14 Current studies with enzymes from bee venom, such as secreted phospholipase A 2 type III (sPLA 2 -III), have indicated that sPLA 2 -III can also act on DC † These two authors contributed equally to this work. membranes mobilizing lipid mediators and inducing their maturation. 15 Mammalian-secreted PLA 2 s present many catalytic and structural similarities with venom phospholipases, they are extracellular low-molecular-mass (13-18 kDa) enzymes that have 6-8 disulphide bridges, and require millimolar concentrations of Ca 2þ for enzymatic activity. 16 The plasma of patients with various inflammatory diseases, particularly atherosclerosis, contains high concentrations of the isoform sPLA 2 -IIA, and clinical studies reveal a correlation between circulating levels of the phospholipase and vascular complications. 17 sPLA 2 -IIA, which can be upregulated by inflammatory cytokines, such as IL-1b, IL-6, and TNFa, acts as an acute phase reactant in chronic inflammatory diseases and it is clearly linked to the development of atherosclerotic lesions. 18, 19 It has been detected in atherosclerotic arteries and may trigger its effects on all the atheroma-associated cells. sPLA 2 -IIA is present in VSMC from both media and intima layers and in macrophage-rich regions of atherosclerotic plaques, and it may induce foam cell formation and lowdensity lipoprotein modification. 20, 21 To date, details of sPLA 2 -IIA actions and its precise physiological and/or pathophysiological role have not yet been defined. Although this enzyme is involved in the specific synthesis of lysophosphatidic acid, unesterified fatty acids, and prostaglandins, and most of its biological activities have been attributed to its capacity to generate biologically active lipids, which may sustain inflammation, several lines of evidence suggest a mechanism of action involving the human M-type receptor, or a related structure, as the mediator of its effects. [22] [23] [24] In this work, we examined the role of sPLA 2 -IIA in monocyte biology and we found that sPLA 2 -IIA can act on THP-1 cells to induce a monocyte-derived dendritic cell (MDDC) phenotype, emphasizing the role of this secreted enzyme in the regulation of immune responses and its implication in atherosclerotic processes.
Methods

Materials
A C127 mouse fibroblast cell line stably transfected with the coding sequence of sPLA 2 -IIA from human placenta was used as a source of human recombinant enzyme. sPLA 2 -IIA was purified as described previously. 23 FITC-phalloidin, FITC-dextran, PMA, and other chemicals were from Sigma Chemical Co. (St Louis, MO, USA). Recombinant TNFa and IL-4 were from Calbiochem. Monoclonal anti-human DC-SIGN was a generous gift from Dr A.L. Corbí (Centro de Investigaciones Biologicas, CSIC, Madrid, Spain).
Cell culture
THP-1 cells were cultured at 378C under 5% CO 2 atmosphere in RPMI 1640 (GIBCO) with 100 U/mL penicillin/streptomycin, 2 mM glutamine, and 5% FCS and maintained around 5 Â 10 5 cells/mL.
Cell isolation from peripheral blood and monocyte-derived dendritic cell generation
Human monocytes were purified and differentiated according to standard procedures. 25 Briefly, peripheral blood mononuclear cells were isolated from fresh buffy coats (provided by the Center for Hemotherapy of Castilla y León) by lymphoprep density-gradient centrifugation. Then, cells were washed and centrifuged at 1500 r.p.m. to avoid platelets. After 1 h of plastic adherence at 378C in RPMI 1640 with 10% FCS, non-adherent cells were removed by various vigorous washes with PBS and used as T cells in the mixed-leucocyte reaction (MLR) assay. The remaining adherent cells were subsequently differentiated with 1 mg/mL sPLA 2 -IIA or 0.2 mM of PMA þ 1000 U/mL of IL4 for the indicated days.
FITC-dextran uptake by mononuclear cells
Human THP-1 cells or human monocytes were incubated with vehicle, 1 mg/mL sPLA 2 -IIA, 0.2 mM of PMA, or 0.2 mM of PMA þ 1000 U/mL of IL4. After 72 h, cells were suspended in culture medium with 1 mg/mL FITC-dextran (MW 40 000) and incubated at 48C (for background control) or at 378C for 30 min. Then, cells were washed with cold PBS containing 1% FCS, and the FITC-dextran incorporated was analysed by flow cytometry in an EPICSw XL-MCL cytofluorometer (Coulter). The endocytic activity is expressed as the mean fluorescence intensity (MFI) index. MFI index is calculated as fluorescence of FITC-positives cells at 378C minus fluorescence of FITC-positive cells at 48C and normalized at 100 for the control.
Flow cytometry
THP-1 cells were analysed for CD 11b, CD11a, CD11c, CD1a, CD83, CD40, CD14, CD61, CD62L, DC-SIGN, or ICAM expression (Pharmingen, San Diego, CA, USA). Control and treated cells were collected for immunolabelling with 10 mg/mL of each indicated antibody for 1 h at 48C, followed by PE-or FITC-conjugated secondary antibody (Sigma). Subsequently, cells were washed, resuspended in 500 mL of PBS and analysed by flow cytometry. Positive cells were estimated using P3-X63 myeloma supernatant as a negative control or an isotype-matched control-negative antibody at an equivalent concentration. Data analysis was performed using WinMDI 2.7 software.
THP-1 cell morphology
THP-1 cells were seeded on glass coverslips (1.2 Â 10 4 cells/slip). Then, cells were stimulated for 72 h. After that, cells were washed with PBS, fixed for 10 min with 3.7% formaldehyde/PBS, and permeabilized for 5 min with 0.3% Triton X-100/PBS. Actin morphology was assessed by staining with FITC-phalloidin and was visualized using a Bio-Rad laser scanning Radiance 2100 system coupled to a Nikon Eclipse TE-2000U confocal microscope with a Â60 oil objective.
Assessment of morphological changes and adhesion assay
Under normal culture conditions, THP-1 cells remain in suspension; however, after treatment with sPLA 2 -IIA, a subpopulation of cells become adherent. Morphological changes of the adherent cells were assessed by phase-contrast microscopy. In addition, adherent cells were quantified by using the [methyl- The labelled cells were stimulated with 1 mg/mL of sPLA 2 -IIA, 0.2 mM of PMA, or 0.2 mM of PMA þ 1000 U/mL IL-4 at 378C for the indicated times. Then, the plates were rinsed four times with PBS, adherent cells were scraped, and the amount of radioactivity present was determined by liquid scintillation counting.
Chemotaxis assay
Chemotaxis assay was performed in a six-well plate using tissue culture polycarbonate filter inserts (3 or 8 mm pore, Corning, Costar, Cambridge, MA, USA) blocked with BSA. THP-1 cells (5 Â 10 6 ) were resuspended in 1 mL of serum-free medium, loaded into the upper chamber of an insert, and incubated at 378C. The lower chamber contained conditioned medium from cells incubated with either vehicle, 100 U/mL of TNF-a, or 1 mg/mL of sPLA 2 for 18 h. sPLA 2 -IIA and atherosclerosis After 45 min, the membrane was removed, and the cells in the lower chamber were recovered and counted in a cytofluorometer. The results are expressed as the fold increase over the control.
Allogeneic mixed-leucocyte reaction: T cell proliferation assay
The immunostimulatory capacities of the sPLA 2 -IIA-treated THP-1 cells to activate T cells was measured in an MLR and quantified by the MTS assay (Cell Tilter 96TM Non-Radioactive Cell Proliferation Assay, Promega, Inc.) method, according to the manufacturer's recommendations.
THP-1 cells were differentiated for 5 days with 1 mg/mL sPLA 2 -IIA or 0.2 mM of PMA þ 1000 U/mL of IL4 (effector cells) and treated with 50 mg/mL mitomycin C (Sigma) for 20 min at 378C to inhibit cell proliferation. After extensive washes, various numbers (10 ) of these differentiated THP-1 cells (THP-1-DC) were added to freshly isolated 10 4 lymphocytes (responder cells). Triplicates of the co-culture were incubated for 3 days in 96-well roundbottom microtitre plates, and the proliferative T cell response was quantified by the addition of MTS solution (20 mL/well). After 1 h incubation, the conversion of MTS to formazan was measured at 490 nm in a microplate reader (VERSAmax, Molecular Devices, CA, USA). As control, lymphocytes were cultured in the absence of THP-1-DC. For data analysis, the actual absorbance values from the co-culture were adjusted for the background absorbance of THP-1-DC. Proliferation index was calculated as the ratio of the corrected absorbance for a specific experimental condition to the absorbance of control culture (lymphocytes alone).
Data presentation
Numerical data are expressed as means + SD and analysed with the GraphPad Prism Version 4 software (San Diego, CA, USA) for statistical significance using the one-way ANOVA test, followed by Dunnett's multiple comparison test to compare differentiated cells to untreated control cells. P , 0.05 was considered significant.
Results
Secreted phospholipase A 2 type IIA promotes THP-1 monocyte differentiation
We studied the capacity of sPLA 2 -IIA to modulate monocyte differentiation into either macrophages or DCs. In order to characterize the phenotypic modifications elicited by sPLA 2 -IIA, we used a well-characterized human promonocytic cell line, THP-1, since these cells have been extensively considered a valuable model system for monocyte-macrophage differentiation and for studying intracellular sPLA 2 -IIA-signalling pathways. Thus, THP-1 cells were stimulated with the phospholipase, and the expression of CD14 was analysed in the culture after 24, 48, and 72 h by flow cytometry. As shown in Figure 1A , the treatment with 1 mg/mL sPLA 2 -IIA triggered a time-dependent downregulatory effect on CD14 surface expression. To define the dosedependency of the action of the sPLA 2 -IIA, cells were incubated for 24 h with different concentrations of sPLA 2 -IIA. Figure 1B shows the effects of the different concentrations of sPLA 2 -IIA on CD14 downregulation. The optimal effect took place at a concentration of 1 mg/mL sPLA 2 -IIA, which is the concentration used in experiments to follow.
Apart from CD14 downregulation, also morphological changes in THP1 can be observed after incubation with the phospholipase. Figure 2A illustrates cellular morphology studies under phase-contrast microscopy, where it is shown that, in the presence of the phospholipase, cells became adherent, formed homotypic aggregates, and displayed cytoplasmic protrusions, characteristic morphology of DCs. Cell clustering began 24 h following sPLA 2 -IIA stimulation and was further enhanced after 48-72 h. We also incubated THP-1 cells with PMA þ IL-4, known to induce phenotypic and functional MDDCs. As shown in Figure 2A , this treatment yielded similar results to those found with the phospholipase. Moreover, cells were stained for F-actin and observed under confocal ( Figure 2B , upper panels) or conventional ( Figure 2B , lower panels) fluorescence microscope; the studies revealed that sPLA 2 -IIA-treated THP-1 cells also developed morphological changes suggestive of MDDC, since they exhibited numerous projections and a laterally positioned nucleus, similar to what it is induced after PMA þ IL-4 treatment. In addition, the modulation of CD14 was also evaluated in fluorescence immunostaining experiments. As shown in Figure 2C , the signal corresponding to CD14, constitutively expressed in control cells, was barely detectable after differentiation.
The effect found on CD14 surface expression after sPLA 2 . 25 Next, sPLA 2 -IIA was added simultaneously to PMA and IL-4, and flow cytometry analysis revealed minor effects on both CD14 (62% positive cells and 47 MFI) and DC-SIGN (86% positive and 60 MFI) expressions, compared with the induction found after either the combination PMAþIL-4 or the phospholipase alone ( Figure 3A) . Interestingly, the same effect was also observed in human monocytes ( Figure 3C ). The modulation of DC-SIGN was also evaluated by western blot and by fluorescence immunostaining experiments. As shown in Figure 3B , the signal corresponding to DC-SIGN greatly increased in cells treated with either sPLA 2 -IIA or PMA and IL-4 compared with untreated cells.
To go deeper into the phenotype of sPLA 2 -IIA-treated THP-1 monocytes, flow-cytometrical analysis of monocyte/ dendritic surface antigens was performed (Figure 4 ). The histograms demonstrate that after sPLA 2 -IIA stimulation, cells share immunophenotypic features with PMA þ IL-4-differentiated THP-1: CD14 was clearly downregulated and cells increased the level of the expression of the surface markers CD54 (ICAM-1), CD62L, and CD61, as well as the costimulatory molecules CD40 and CD83. However, although no significant differences were found in the presence of CD1a, CD18, CD11a, CD11b, or CD11c at any time point in sPLA2-IIA-treated cells, the presence of PMA þ IL-4 led to an upregulation of CD11a, CD11b, CD1a, and CD18. In addition, neither the membrane mannose receptor (CD206) nor CD36, both markers of macrophages, were upregulated by the presence of sPLA 2 -IIA (data not shown). sPLA 2 -IIA and atherosclerosis 3.2 Effects of secreted phospholipase A 2 type IIA on functional cellular processes 3.2.1 Regulation of endocytosis by secreted phospholipase A 2 type IIA Antigen uptake in immature DCs occurs primarily through endocytosis, and this ability is critical for the immunological function of these cells. However, this skill of efficient internalization of antigens is progressively lost during the maturational process, as mature DCs become focused on presenting antigens. 26 To determine the endocytic capacity of both sPLA 2 -IIA-treated THP-1 cells (Figure 5A and B) and monocytes ( Figure 5C and D) , untreated and treated cells were incubated with the probe FITC-dextran, since it allows quantitation by flow cytometry analysis. Figure 5A and C shows FITC-dextran beads accumulation at 378C in cells differentiated with the indicated agonist. Approximately 80% of the THP-1 cells became FITC-dextran-positive after 1 h of incubation with sPLA 2 -IIA, and 95% after PMA or PMA þ IL-4 treatment. The narrow distribution of the fluorescence profile in the histograms indicates that all the cells of a particular condition take up comparable amounts of the probe; however, diverse MFI are observed between treatments owing to different efficiency in antigen capture. Similar behaviour was observed in monocytes, although in these cells the maximal response was found after PMA þ IL-4 exposure. For statistical analysis, MFI values were normalized to 100 of control non-treated cells ( Figure 5B and D) .
Regulation of T cell stimulatory capacity: mixed lymphocyte reaction
Next, to evaluate the antigen-presenting function of sPLA 2 -IIA-treated THP-1 cells, their ability to stimulate the proliferation of allogeneic lymphocytes was assessed by the MLR. As shown in Figure 6A , we found that sPLA 2 -IIA-treated THP-1 cells were able to strongly stimulate the proliferation of lymphocytes, although their antigen-presenting ability was weaker than that of PMA þ IL4-treated cells. This T cell stimulatory capacity of the differentiated THP-1 cells was in line with the phenotypic changes shown previously. The proliferative response rate correlated with the THP-1-DC/lymphocytes ratio. When untreated THP-1 cells were co-cultured with 10 4 lymphocytes at a ratio of 1:1, the proliferation index was 1.7 + 0.3, meaning a 40 and 30% of the T cell proliferation induced by sPLA 2 -IIA-or PMA þ IL4-stimulated THP-1 cells, respectively, at the same ratio. Therefore, sPLA 2 -IIA generates cells that possess the capacity to trigger functionally relevant interactions with T lymphocytes.
Regulation of chemotaxis by secreted phospholipase A 2 type IIA
The recruitment of DCs from the site of residence to the T cell areas is another essential event in the induction of primary immune responses, and several lines of evidence indicate that their migration is promoted by locally produced inflammatory cytokines such as TNFa. 27 To determine the migratory capacity of the cells in response to sPLA 2 Figure 6B ). With the 3 mm pore inserts, the migration of THP-1 cells exposed to sPLA 2 -IIA supernatant was sensibly diminished, whereas those exposed to TNFa supernatants showed similar levels of chemotaxis to the 8 mm pore inserts. When the lower chambers contained media plus sPLA 2 -IIA, no chemotactic effect was observed. In addition, we examined the migration of sPLA 2 -IIA-treated cells exposed to sPLA 2 -IIA supernatant, and we observed that there was no significant difference, compared with cells exposed to control media (data not shown).
Regulation of adherence by secreted phospholipase A 2 type IIA
The differentiation of monocytes to either macrophages or DC is accompanied by changes in their ability of adhesion to extracellular matrices. To test the ability of sPLA 2 -IIA to affect cell adherence, [ 3 H]-thymidine-labelled THP-1 monocytes were aliquoted into six-well plastic plates and incubated for 12 or 24 h with the enzyme, PMA þ IL-4, or PMA alone (as a reference agonist). As shown in Figure 6C , sPLA 2 -IIA, as well as PMA or PMA þ IL-4, was found to increase, in a time-dependent manner, the adherence of THP-1 cells to plastic surfaces. Although, PMA-and PMA þ IL-4-treated THP-1 monocytes showed higher adhesive ability than sPLA 2 -IIA-treated cells, after 48 h the adherence induced by both agents showed similar levels of increase than at 24 h.
Discussion
Inflammation plays an important role in atherosclerosis, contributing to the recruitment of inflammatory cells into the lesions, where they turn into macrophages, foam cells, or dendritic cells, causing plaque instability, which is the main process that elicits cardiovascular events. It is well demonstrated that cardiovascular risk factors, such as oxidized-LDL, nicotine, or some acute-phase reactants (APR), cause the modulation of the immune system. [28] [29] [30] Among APR found enhanced in serum of patients with coronary artery disease, high circulating levels of C-reactive protein and sPLA 2 -IIA have been observed, but, although Creactive protein role in DC differentiation, maturation, and functions have been assessed, little is known about how secreted phospholipases affect this process. 30 Several attempts have been performed with bee venom PLA 2 and the catalytic domain of human sPLA 2 -III on DC maturation and activation, 12, 31 but the role in immunity and/or in the tolerance of the sPLA 2 enzymes present in human inflammatory lesions, such as sPLA 2 -IIA, sPLA 2 -V, or sPLA 2 -X, still has to be addressed. This work is the first to evaluate the potential immunomodulatory effects of the human sPLA 2 -IIA. In this study, human THP-1 monocytes, widely used as a monocyte/macrophage differentiation model, were characterized following incubation with the secreted enzyme. We show that, upon treatment, THP-1 cells display the following: (i) upregulation of surface markers CD83, CD40, DC-SIGN, CD54, CD61, and CD62L; (ii) downregulation of surface marker CD14; (iii) appearance of typical dendritic morphological features; (iv) adhesion and migration; (v) increased endocytic activity; and (vi) induction of allogeneic lymphocyte proliferation. Therefore, we conclude that sPLA 2 -IIA, an enzyme present in the atherosclerotic lesions, is able to induce the differentiation of THP-1 monocytes into MDDCs or, alternatively activated macrophages, similar to what is observed with the classical combination of PMA þ IL-4. 25 Moreover, the studies that we performed in human monocytes to validate these responses confirmed that the differentiation activity of the phospholipase is not restricted to THP-1 cells.
Previously, it had been suggested that the participation of inflammatory-secreted PLA 2 s, including group IIA, V, or X, on DC maturation in vivo, is due to their ability to modify LDL, rather than phospholipases themselves. 32, 33 However, here we show that it is the action of sPLA 2 -IIA itself on THP-1 monocytes which promotes the phenotypic and morphological modifications.
In atherosclerotic arteries, sPLA 2 -IIA occurs in both cellular and extracellular elements, and it has been found associated to SMC and macrophages/foam cells. 20 Therefore, we can hypothesize that sPLA 2 -IIA released by SMC may induce a dendritic cell-like phenotype in adjacent monocytes/ macrophages, acting as an amplifier of the inflammatory responses and enabling these cells to present antigens and support an immune response. 4 peripheral blood T lymphocytes were cultured with RPMI alone or with various numbers of these mitomycin C-treated THP-1 dendritic cells. After a 3 day co-culture, proliferation was determined using the MTS assay, the proliferation index calculated as described in Methods. Optical density at 490 nm in the culture containing lymphocytes with RPMI alone (control) was 0.175 + 0.032; n ¼ 3. *P , 0.001 vs. RPMI alone. (B) The migratory capacity was determined using 3 and 8 mm pore-size Transwell plaques, as indicated in Methods. The results are presented as a migration index denoting the fold increase of cell migration over control. *P , 0.001 vs. control. (C ) THP-1 adherence was determined after 12 or 24 h stimulation with solvents (control), 1 mg/mL secreted phospholipase A 2 type IIA, 0.2 mM PMA, or 0.2 mM PMA þ 1000 U/mL IL4, as described in Methods. *P , 0.05, **P , 0.01 vs. control. Each bar represents mean + SD (n ¼ 3). sPLA 2 -IIA-treated THP-1 cells are, in many ways, comparable with in vitro-differentiated monocytes in the presence of PMA þ IL-4. They become clustered and develop the clearly characteristic dendritic morphology, as well as the capacity to capture FITC-dextran. However, although they share the basic DC phenotype, the analysis of the expressed membrane markers demonstrates some differences between them, for instance, although after PMA þ IL-4 differentiation cells acquire high expression levels of CD11b, CD11c, CD1a, and CD18, sPLA 2 -IIA treatment does not affect their expression.
It has been suggested that depending on the local microenvironment, MDDC can adopt different membrane-marker profiles, which could have major influences on cell-cell interactions and antigen uptake and presentation. Thus, the absence of CD1a expression has also been found in DCs derived from human monocytes in the presence of dexamethasone. 34 In addition, and consistent with the role of CD1a in the allogenic T cell response, dexamethasone DC has lower T cell stimulatory activity. In keeping with that, although we have observed that sPLA 2 -treated THP-1 cells present the ability to induce higher lymphocyte proliferation than resting ones, their allostimulatory function is weaker than that induced by PMA þ IL4 differentiation, which also elicits CD1a upregulation.
Another crucial function of DCs is the capacity to capture exogenous antigens: the endocytic activity. We found that sPLA 2 -IIA significantly altered the processes of endocytosis and the expression of some phagocytic receptors on THP-1 cells. The endocytic capacity of sPLA 2 -IIA-treated cells was significantly enhanced, although at a lower extent than PMA þ IL-4-differentiated cells. However, the expression of DC-specific ICAM-3-grabbing non-integrin was largely upregulated in both conditions. This increase on surface DC-SIGN expression presents a special relevance, given that studies on plaques from human coronary and carotid arteries and aorta reveal the presence of DC-SIGN-immunoreactive cells. 10 In addition, since this DC-specific lectin molecule has been implicated as a receptor used by various microorganisms associated with chronic infection, its upregulation on sPLA 2 -IIA-treated cells may also have important consequences for pathogen clearance. Thus, THP-1 differentiation in the presence of sPLA 2 -IIA at the sites of inflammation may directly play a role in antigen loading, presentation capabilities, and, therefore, in the immune response. Interestingly, we (and others) detect at least three DC-SIGN bands in differentiated cells; it has been suggested that they may represent differential glycosylation of a DC-SIGN isoform or be derived from alternatively spliced mRNA but it is still under investigation. 25 In addition, the observed upregulation of CD83, a typical marker of DCs, was also recently reported for monocytederived DCs treated with sPLA 2 -III from bee venom. 12 The adhesion molecules, CD54 (involved in leucocyte trafficking towards inflammatory stimuli) and CD62L (the homing receptor), are also increased during the time-course analysis, although CD18, also required for migration, is not modulated. The expression of co-stimulatory molecules, such as CD40, also increased following 24 h of phospholipase stimulation. Therefore, the expression marker profile induced by sPLA 2 -IIA resembles an intermediate stage between immature and mature MDDC.
It is generally accepted that many types of DCs exist, with subtle differences in phenotype markers, and there is a wide array of factors that regulate monocyte differentiation, playing a critical role on the heterogenous phenotype of DC. Thus, depending on the presence of specific cytokines, monocyte differentiation switches from dendritic cells to macrophages, or from macrophages to DC. 35, 36 Factors, such as cyclic nucleotides, promote monocyte differentiation towards an intermediate cell type between macrophages or DCs. 37 Even foam cell-inducing agents, such as native LDL and oxLDL, promote a dendritic cell-like phenotype on macrophages. 38 In conclusion, this work shows that the immunostimulatory activity of secreted phospholipases is not restricted to the induction of DC maturation, but can also be considered environmental factors, at the inflammatory site, that affect the differentiation process of monocytes, playing a crucial role in the interface among innate and adaptive immunity.
Increased PLA 2 levels in atherosclerotic arteries may be a critical factor to regulate dendritic cell formation in lesions favouring the development of the adaptive arm of immunity and, in turn, influencing composition, inflammatory nature, and plaque growth. The regulation of the sPLA 2 expression in the atherosclerotic lesion could be a strategy in order to avoid plaque instability and, therefore, a worsening of the prognosis of the pathology.
Funding
This work was supported by Plan Nacional de Salud y Farmacia (SAF2005-01242) and Junta de Castilla y Leon (CSI11A08). M.H. is under the Ramon y Cajal Program (co-funded by F.S.E.). E.I. and R.M. are supported by a fellowship from the Spanish Ministerio de Educación y Ciencia.
